Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

FDA Trader Talk Trading Halts

Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMDApril 26, 2016 5:58 AM FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)April 25, 2016 6:12 PM FDA Panel Starts Getting Cautious on Sarepta's (SRPT) EteplirsenApril 25, 2016 12:19 PM Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected HaltApril 25, 2016 6:40 AM Form 4 Sarepta Therapeutics, For: Apr 20 Filed by: Kaye Edward M. MDApril 22, 2016 4:37 PM Baird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking Move' by FDAApril 22, 2016 2:57 PM Sarepta (SRPT) Voting Questions Rekindle Hope, but RBC Still Expects a Negative PanelApril 22, 2016 2:22 PM FDA Draft Questions Changes Calculus on Sarepta (SRPT) Approval 'to Some Extent' - Janney Montgomery ScottApril 22, 2016 1:35 PM Leerink Remains Skeptical Despite FDA Draft Questions on Sarepta (SRPT)April 22, 2016 1:28 PM